Skip to content

Study · Observational study · 2026

3 results

Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System.

Ohyama K, Abe N, Okamoto T, Hori Y

International journal of clinical pharmacology and therapeutics1 Jan 2026

PMID41122011 (opens in a new tab)DOI10.5414/cp204789 (opens in a new tab)PepBankPUB-41122011
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studySafety outcome

    In the pharmacovigilance database, dulaglutide exposure was inversely associated with fracture reports.

    In plain wordsDulaglutide use was linked to fewer fracture reports in the pharmacovigilance database.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFracture reporting association
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Inverse associations were observed between incretin-related drugs and fractures in patients treated with DPP-4Is (sitagliptin) and GLP-1RAs (dulaglutide, exenatide, and liraglutide).
    1 context sentence
    Summary · context
    Data from the U.S. Food and Drug Administration Adverse Event Reporting System from the first quarter of 2013 to the end of 2019 were analyzed. The reporting odds ratio and information component values were used to evaluate the positive and inverse associations between the abovementioned drugs and fractures.
  2. 02HumanObservational studySafety outcome

    In the pharmacovigilance database, liraglutide exposure was inversely associated with fracture reports.

    In plain wordsLiraglutide use was linked to fewer fracture reports in the pharmacovigilance database.

    Peptide
    Liraglutide
    Outcome
    DecreaseFracture reporting association
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Inverse associations were observed between incretin-related drugs and fractures in patients treated with DPP-4Is (sitagliptin) and GLP-1RAs (dulaglutide, exenatide, and liraglutide).
    1 context sentence
    Summary · context
    Data from the U.S. Food and Drug Administration Adverse Event Reporting System from the first quarter of 2013 to the end of 2019 were analyzed. The reporting odds ratio and information component values were used to evaluate the positive and inverse associations between the abovementioned drugs and fractures.
  3. 03HumanObservational studySafety outcome

    Among patients receiving pioglitazone, liraglutide exposure was inversely associated with fracture reports.

    In plain wordsAmong pioglitazone users, liraglutide use was linked to fewer fracture reports.

    Peptide
    Liraglutide
    Outcome
    DecreaseFracture reporting association
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A subgroup analysis revealed inverse associations between fractures and GLP-1RAs (exenatide and liraglutide) in patients treated with pioglitazone.
    1 context sentence
    Summary · context
    Data from the U.S. Food and Drug Administration Adverse Event Reporting System from the first quarter of 2013 to the end of 2019 were analyzed. The reporting odds ratio and information component values were used to evaluate the positive and inverse associations between the abovementioned drugs and fractures.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.